Acyclovir and ebv

Acyclovir and ganciclovir may reduce EBV shedding, but are ineffective clinically. Treatment of immunocompromised patients with EBV

Acyclovir is an antiviral medication that inhibits DNA polymerase of EBV. Acyclovir s effects on IM have been studied in double-blind, placebo-controlled trials and have demonstrated a suppression in the shedding of EBV in the saliva of infected patients, but EBV replication resumed after treatment was discontinued. 12,13 The use of acyclovir

EBV replicates during lytic infection by mechanisms common to all herpesviruses, and EBV lytic infection is inhibited by nucleoside analogues such as acyclovir

Acyclovir/ganciclovir: no role in IM. Reduces EBV shedding in the mouth, but no clinical benefit. Ganciclovir employed by some for EBV CNS

The role of antiviral therapies in the treatment of acute and chronic EBV-associated disease is unclear. Acyclovir reduces EBV replication by inhibiting viral DNA polymerase, and studies have found that both acyclovir and the prodrug valacyclovir reduce oral shedding of EBV in patients with infectious mononucleosis.

Acyclovir and ganciclovir may reduce EBV shedding, but are ineffective clinically. Treatment of immunocompromised patients with EBV

No effective antiviral therapy is available for Epstein-Barr virus (EBV) infectious mononucleosis in immunocompetent persons. Acyclovir and ganciclovir may reduce EBV shedding, but are ineffective clinically. Treatment of immunocompromised patients with EBV lymphoproliferative disease is controversial. Acyclovir has not been proven to be

As acyclovir and ganciclovir inhibit EBV in vitro [11,34,35], these drugs and their oral prodrugs were evaluated for suppression of EBV reactivation during immunosuppression. PTLD incidence in lung and heart-lung transplant EBV-seronegative recipients was reduced by antiviral prophylaxis with acyclovir, valacyclovir or ganciclovir . The

Antiviral therapy. Acyclovir is most active in vitro against HSV, with activity against VZV being about tenfold less. Although EBV has only minimal thymidine kinase activity, EBV DNA polymerase is susceptible to inhibition by acyclovir triphosphate and thus EBV is moderately susceptible to acyclovir in vitro.